Abstract 485P
Background
Integrins are known to play a crucial role in the adhesion, invasion and migration of tumor cells. Recent studies revealed the association of certain integrin subunits in organotropic metastasis of breast cancer. In this study, we investigated the biological properties associated with different integrin subunits gene expression in CTCs.
Methods
The study included 81 patients with non-metastatic invasive breast carcinoma of no special type (T1-4N0-3M0, all molecular subtypes). Single-cell cDNA libraries were prepared using the Single Cell 3′ Reagent Kit v3.1 and a 10x Genomics Chromium Controller. The ready cDNA libraries were sequenced on NextSeq 500 and NextSeq 2000 (Illumina, USA).
Results
CTCs were identified based on the expression of one or more epithelial markers: KRT5, 7, 8, 14, 18, EPCAM, MUC1 and CDH1 (E-cadherin). In total, expression of 14 integrin subunits was detected in CTCs: nine α-subunits and five β-subunits. In each cell, the combination of different integrin subunits was evaluated, and if complementary α and β-subunits gene expression detected in one cell, we suggested that CTCs potentially could synthesize functionally complete integrin heterodimers. Depending on the combinations of different subunits in CTCs, 455 cells were divided into nine groups. In each group, we assessed the proportion of cells with expression of genes relevant to the most important functions that determine the malignant potential of tumor cells: stemness, EMT, invasion. The most differences were observed in the group of CTCs potentially capable to express the α6β4 heterodimer. Namely, integrins α6- and β4-positive CTCs more frequent expressed stemness (ALDH1A1, CD133, KLF4, MYC) and invasion markers (RAC1, RHOC, ROCK, MMP1,2). A combination of epithelial (KRT 8, 10, 18, 19 and MUC1) with mesenchymal features (absence of EPCAM expression, expression of CDH2, VIM, ZEB1) indicates a hybrid state of EMT.
Conclusions
A novel approach to scRNA sequence analysis has identified subpopulations of CTCs with pronounced biological properties which can play role of "seeds". The simultaneously presence of integrin α6 and β4-subunits in CTCs was associated with stemness, EMT and invasiveness of CTCs in breast cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The study was supported by the Russian Science Foundation (grant #21-15-00140).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
447P - Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: A systematic review and meta-analysis
Presenter: Lixi Li
Session: Poster session 04
448P - Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
Presenter: Hossameldin Abdallah
Session: Poster session 04
449P - Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study
Presenter: Claudia von Arx
Session: Poster session 04
450P - A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2-negative advanced breast cancer
Presenter: Ying Zhang
Session: Poster session 04
451P - Breast Cancer Lighthouse study: 1 year follow-up results of ribociclib treatment patterns and clinical outcomes in a real-world Portuguese cohort
Presenter: Beatriz Gosalbez Pequeno
Session: Poster session 04
452P - A phase II trial of anlotinib and fulvestrant in patients with metastatic breast cancer previously treated with an aromatase inhibitor
Presenter: Xiaojia Wang
Session: Poster session 04
453P - Clinical outcomes of pyrotinib-based therapy after prior trastuzumab and pertuzumab in HER2-positive metastatic breast cancer
Presenter: Jinmei Zhou
Session: Poster session 04
454P - Real-world genomic profiling of patients with advanced or metastatic triple-negative breast cancer in the UK and EU4: A systematic literature review
Presenter: Barinder Singh
Session: Poster session 04
455P - Post progression treatments after endocrine therapy (ET) plus palbociclib in patients with HR+/HER2- metastatic breast cancer (MBC): A prospective, real-world study
Presenter: Raffaella Palumbo
Session: Poster session 04